Hangzhou Tigermed Consulting Co Ltd
SZSE:300347

Watchlist Manager
Hangzhou Tigermed Consulting Co Ltd Logo
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Watchlist
Price: 61.33 CNY -5.5% Market Closed
Market Cap: 45.5B CNY
Have any thoughts about
Hangzhou Tigermed Consulting Co Ltd?
Write Note

Hangzhou Tigermed Consulting Co Ltd
Accrued Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Hangzhou Tigermed Consulting Co Ltd
Accrued Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accrued Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Accrued Liabilities
ÂĄ346m
CAGR 3-Years
25%
CAGR 5-Years
28%
CAGR 10-Years
46%
WuXi AppTec Co Ltd
SSE:603259
Accrued Liabilities
ÂĄ2.2B
CAGR 3-Years
10%
CAGR 5-Years
26%
CAGR 10-Years
N/A
Pharmaron Beijing Co Ltd
SZSE:300759
Accrued Liabilities
ÂĄ732.6m
CAGR 3-Years
17%
CAGR 5-Years
28%
CAGR 10-Years
N/A
WuXi Biologics (Cayman) Inc
HKEX:2269
Accrued Liabilities
ÂĄ393.2m
CAGR 3-Years
-1%
CAGR 5-Years
28%
CAGR 10-Years
N/A
M
MGI Tech Co Ltd
SSE:688114
Accrued Liabilities
ÂĄ310.1m
CAGR 3-Years
0%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
W
WuXi XDC Cayman Inc
HKEX:2268
Accrued Liabilities
ÂĄ74.9m
CAGR 3-Years
109%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Hangzhou Tigermed Consulting Co Ltd
Glance View

Market Cap
45.5B CNY
Industry
Life Sciences Tools & Services

Hangzhou Tigermed Consulting Co., Ltd. is a leading clinical trial and consulting organization based in China, dedicated to facilitating the development of innovative medical therapies. Founded in 2002, the company has rapidly ascended to prominence by leveraging its deep expertise in clinical research while providing comprehensive services that encompass all phases of clinical trials. With a robust portfolio that includes over 4,000 completed projects, Tigermed stands out for its strong focus on quality, efficiency, and regulatory compliance. Serving a diverse clientele of pharmaceutical and biotechnology companies, the firm positions itself as a vital partner in navigating the complexities of the drug development process, particularly in fast-growing Asian markets. An investor looking at Tigermed will find a company that is not only well-established but also poised for significant growth amidst rising global healthcare demands. With a strategic emphasis on expanding its geographic footprint and enhancing technological capabilities, Tigermed is capitalizing on the increasing investment in life sciences, particularly in China and surrounding regions. By harnessing big data analytics and innovative methodologies, the company is well-equipped to streamline clinical operations, reduce costs, and accelerate time-to-market for life-saving treatments. As the global healthcare landscape continues to evolve, Tigermed’s commitment to fostering advancements in clinical research places it in an advantageous position, making it an attractive prospect for investors seeking exposure in the burgeoning healthcare sector.

Intrinsic Value
70.64 CNY
Undervaluation 13%
Intrinsic Value
Price

See Also

What is Hangzhou Tigermed Consulting Co Ltd's Accrued Liabilities?
Accrued Liabilities
346m CNY

Based on the financial report for Sep 30, 2024, Hangzhou Tigermed Consulting Co Ltd's Accrued Liabilities amounts to 346m CNY.

What is Hangzhou Tigermed Consulting Co Ltd's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 10Y
46%

Over the last year, the Accrued Liabilities growth was 49%. The average annual Accrued Liabilities growth rates for Hangzhou Tigermed Consulting Co Ltd have been 25% over the past three years , 28% over the past five years , and 46% over the past ten years .

Back to Top